694 related articles for article (PubMed ID: 19530674)
1. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
Shokeen M; Anderson CJ
Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
[TBL] [Abstract][Full Text] [Related]
2. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.
Anderson CJ; Ferdani R
Cancer Biother Radiopharm; 2009 Aug; 24(4):379-93. PubMed ID: 19694573
[TBL] [Abstract][Full Text] [Related]
3. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.
Cai Z; Anderson CJ
J Labelled Comp Radiopharm; 2014 Apr; 57(4):224-30. PubMed ID: 24347474
[TBL] [Abstract][Full Text] [Related]
4. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
5. Copper chelation chemistry and its role in copper radiopharmaceuticals.
Wadas TJ; Wong EH; Weisman GR; Anderson CJ
Curr Pharm Des; 2007; 13(1):3-16. PubMed ID: 17266585
[TBL] [Abstract][Full Text] [Related]
6. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
[TBL] [Abstract][Full Text] [Related]
7. The development of copper radiopharmaceuticals for imaging and therapy.
Shokeen M; Wadas TJ
Med Chem; 2011 Sep; 7(5):413-29. PubMed ID: 21711219
[TBL] [Abstract][Full Text] [Related]
8. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
9. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ
Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in copper radiopharmaceuticals.
Hao G; Singh AN; Oz OK; Sun X
Curr Radiopharm; 2011 Apr; 4(2):109-21. PubMed ID: 22191650
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.
Zeng D; Guo Y; White AG; Cai Z; Modi J; Ferdani R; Anderson CJ
Mol Pharm; 2014 Nov; 11(11):3980-7. PubMed ID: 24720806
[TBL] [Abstract][Full Text] [Related]
13. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside.
Rudd SE; Noor A; Morgan KA; Donnelly PS
Acc Chem Res; 2024 May; 57(9):1421-1433. PubMed ID: 38666539
[TBL] [Abstract][Full Text] [Related]
16. Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold.
Kumar A; Hao G; Liu L; Ramezani S; Hsieh JT; Öz OK; Sun X
Bioconjug Chem; 2015 Apr; 26(4):782-9. PubMed ID: 25760776
[TBL] [Abstract][Full Text] [Related]
17. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
18. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
19. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging.
Anderson CJ; Wadas TJ; Wong EH; Weisman GR
Q J Nucl Med Mol Imaging; 2008 Jun; 52(2):185-92. PubMed ID: 18043536
[TBL] [Abstract][Full Text] [Related]
20. The emerging value of 64Cu for molecular imaging and therapy.
Bolzati C; Duatti A
Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):329-337. PubMed ID: 33026210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
